Citation
Saczewski, Franciszek, et al. "Carbonic Anhydrase Inhibitors: Inhibition of Human Cytosolic Isozymes I and II and Tumor-associated Isozymes IX and XII With S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides." Bioorganic & Medicinal Chemistry, vol. 16, no. 7, 2008, pp. 3933-40.
Saczewski F, Innocenti A, Sławiński J, et al. Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides. Bioorg Med Chem. 2008;16(7):3933-40.
Saczewski, F., Innocenti, A., Sławiński, J., Kornicka, A., Brzozowski, Z., Pomarnacka, E., Scozzafava, A., Temperini, C., & Supuran, C. T. (2008). Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides. Bioorganic & Medicinal Chemistry, 16(7), 3933-40. https://doi.org/10.1016/j.bmc.2008.01.034
Saczewski F, et al. Carbonic Anhydrase Inhibitors: Inhibition of Human Cytosolic Isozymes I and II and Tumor-associated Isozymes IX and XII With S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides. Bioorg Med Chem. 2008 Apr 1;16(7):3933-40. PubMed PMID: 18242998.
TY - JOUR
T1 - Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AU - Saczewski,Franciszek,
AU - Innocenti,Alessio,
AU - Sławiński,Jarosław,
AU - Kornicka,Anita,
AU - Brzozowski,Zdzisław,
AU - Pomarnacka,Elzbieta,
AU - Scozzafava,Andrea,
AU - Temperini,Claudia,
AU - Supuran,Claudiu T,
Y1 - 2008/01/26/
PY - 2007/09/30/received
PY - 2008/01/14/revised
PY - 2008/01/18/accepted
PY - 2008/2/5/pubmed
PY - 2008/5/16/medline
PY - 2008/2/5/entrez
SP - 3933
EP - 40
JF - Bioorganic & medicinal chemistry
JO - Bioorg Med Chem
VL - 16
IS - 7
N2 - A series of S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides has been investigated as inhibitors of four isoforms of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1), that is, the cytosolic, ubiquitous isozymes CA I and II, as well as the transmembrane, tumor-associated isozymes CA IX and XII. The new derivatives were inefficient inhibitors of isoform I (K(I)s in the range of 2.7-18.7 microM) but generally had low nanomolar affinity for the inhibition of the other three isoforms (K(I)s in the range of 2.4-214 nM against hCA II; 1.4-47.5 nM against hCA IX, and 1.7-569 nM against hCA XII, respectively). Some selectivity for the inhibition of the tumor-associated versus the cyctosolic isoform II with some of these compounds has also been evidenced. As CA IX is an important marker of tumor hypoxia and its predictive, prognostic, and druggability potentials for designing antitumor therapies were recently validated, detection of selective, potent CA IX inhibitors may be relevant in the fight against cancers overexpressing CA isozymes.
SN - 1464-3391
UR - https://www.unboundmedicine.com/medline/citation/18242998
DB - PRIME
DP - Unbound Medicine
ER -